Gossamer Bio CEO Faheem Hasnain at #BIO22 (J.T. MacMillan Photography)

Gos­samer lays off 25% of em­ploy­ees, cuts all pro­grams ex­cept PAH drug

As Gos­samer Bio goes all in on its lead drug for pul­monary ar­te­r­i­al hy­per­ten­sion (PAH), it’s cut­ting off all oth­er clin­i­cal and pre­clin­i­cal pro­grams …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.